We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
They could be planning a nice Xmas Present?
"the target" if there is a target
in fact this was one of the com i was researching and thought it will rto with us
Good morning, excellent post Pike,
Yeh no one knows the target. As you said for these tests sensitivity and specificity r very important. The rns mentioned patented; which is excellent for commercialisation. Not sure about the cqc (mainly checking on premises like clinics, hospitals, nursing hs etc..), i ld ”think” that the lse have asked for some sort of clarification/relplies/paperwork etc) hence the delay, hopefully sorted now. Validation? again, i am not sure, usually done through clinical trials, you would think this has been done already. However, not all the tests in the market have been validated before going in the stock market. Lots of speculations but fromwhat i read and hear (as in the article) that cancer screening is gaining attraction from big investors, hoping to see (over subscribed) in the re admission rns.
Today there was an IPO for Sourcebio for 168P ! they are apparently dealing with similar tests, our day will come -:)
https://www.investegate.co.uk/sourcebio-intl-plc/rns/aim-admission---first-day-of-dealings/202010290700075399D/
https://sourcebiointernational.com/business-overview/
Issue is time, the BOD are running out of time and money.
Thanks for sharing Tra1,
Very interesting read and shows what biotech companies in this field are worth.
I’m sure that most, if not all here, have done their research in to this field and discovered like myself, there are a good few companies out there developing/developed (some of whom are not listed btw), this early cancer detection tech. Some target specific types of cancer and others more ‘universal’. Some also on blood tests for tumours that are ‘as yet’ unavailable to the market.
We have all been informed this is a ‘new diagnostic test for the early detection of a cancer’ as per our recent corporate update (note how this has changed from April, when it was specific cancer detection). Maybe nothing.
This led me to research further and you’ll find some who are still ‘currently’ awaiting very recent ‘assay validation’, to provide an assurance of reliability during normal use – evidence that the method does what it is intended to do. Who would verify this? QCQ?
Whilst there have been a number of stinging attacks on our BOD lately (and I’m not defending them by the way), could this be our problem? Issues outside of BOU’s control as communicated so often by Tim at IFC? Perhaps. I know this has been mentioned by a previous poster.
What I am quite confident in is this.
Currently the testing and screening systems for cancer due to COVID are in no way going to return to pre COVID levels for some time to come. Thousands of cancer cases will be going undetected and undiagnosed each week. The NHS will have to adapt to cancer detection and diagnostic services to cope with COVID, not only in suspected cases but also in possible relapsed patients.
Fewer referrals to secondary care and an overall reduced burden on cancer services will push for expanded cancer screening services. Which is where ultimately these companies will come to the forefront in particular those offering easy annual non hospitalised screening.
IF and I say if (as I have absolutely no knowledge that this is coming back or not, although confident) and it’s something along the lines of what I have researched, then we could be at the start of something quite exciting.
Intended only to keep spirits up!
just testing, i can not see my earlier message